1831 / 1851
Toxicity of concurrent SRT and
immune checkpoint inhibition
Anti-PD-1/PD-L1 (nivolumab, pembrolizumab)
Data on combined SRT and nivolumab is
insufficient
for conclusions, both for cranial and
extra-cranial SRT.
Data about the combination of pembrolizumab
with SRT is
not available.
Kroeze S et al. Cancer Treatment Reviews 53 (2017) 25–37